OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books
Oct 8, 2020 • 19min
Dexamethasone
Foundations in #OncoPharm returns to discuss everyone's favorite antineoplastic, dexamethasone, which is also an anti-emetic, and an oncology pre-med among other things.
Oct 1, 2020 • 16min
IMpower 110 & Checkmate 153
Another week, another 2 studies of checkpoint inhibitors in NSCLC to talk about.
IMpower 110: https://www.nejm.org/doi/full/10.1056/NEJMoa1917346
Checkmate-153: https://ascopubs.org/doi/full/10.1200/JCO.20.00131
Sep 24, 2020 • 24min
ESMO 2020 & Beyond
Updates from ESMO 2020 & more on:
Bladder Cancer (JAVELIN Bladder 100 & DANUBE)
Lung Cancer (ADAURA & CROWN)
Breast Cancer (ASCENT, IMPASSION 130/131, monarchE)
And the first major publication of drugging the "undrugable" KRAS
Sep 17, 2020 • 14min
TAX 327
The Landmarks in OncoPharm series returns to discuss a major breakthrough in treating advanced prostate cancer, TAX-327, which at the time established docetaxel as a new standard of care for metastatic prostate cancer that was (at that time) considered hormone-refractory.
TAX 327: https://www.nejm.org/doi/full/10.1056/NEJMoa040720
Sep 11, 2020 • 12min
Pralsetinib
We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.
Sep 3, 2020 • 17min
BROCADE3
After brief diatribes on PO azacitidine and COMBI-AD's 5-year non-OS analysis, we focus on BROCADE3 and the background on BRCA-mutated metastatic breast cancer treatment.
BROCADE3: https://doi.org/10.1016/S1470-2045(20)30447-2
Aug 27, 2020 • 19min
Alopecia
Chemotherapy-induced alopecia is the next in our series on Foundational #OncoPharm topics.
Aug 20, 2020 • 13min
ATAC
Our Landmarks in #OncoPharm Series returns to discuss ATAC: Anastrozole or Tamoxifen Alone or in Combination for adjuvant breast cancer treatment.
Aug 13, 2020 • 16min
VIALE-A (venetoclax + azacitidine for elderly/unfit AML)
VIALE-A: Veneoxlax + azacitidine, a new standard of care for elderly or unfit AML patients, is now published. Lots of supportive care and management concerns to discuss: tumor lysis syndrome, prophylactic anti-microbials, G-CSF use (?), and dose modification for hematologic toxicity.
Link: https://doi.org/10.1056/nejmoa2012971
Aug 6, 2020 • 22min
New Anti-CD-19 And BCMA Options
Lots of new options for B-cell malignancies of all ages!
We discuss brexucabtagene autoleucel (CAR-T for mantle cell lymphoma, tafasitamab (anti CD-19 monoclonal antibody), and belantamab mafadotin (anti-BCMA antibody drug conjugate).
Finally, for good measure we review the newly approved regimen of atezolizumab with vemurafenib/cobimetinib for BRAF-mutated metastatic melanoma.
